Stockholm - Delayed Quote SEK

EQL Pharma AB (EQL.ST)

82.10
-0.40
(-0.48%)
At close: May 9 at 5:29:43 PM GMT+2
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
338,394
264,168
259,913
409,753
179,141
Cost of Revenue
197,497
149,123
144,063
314,019
128,135
Gross Profit
140,897
115,045
115,850
95,734
51,006
Operating Expense
88,499
82,802
74,743
57,175
39,813
Operating Income
52,398
32,243
41,107
38,559
11,193
Net Non Operating Interest Income Expense
-10,516
-5,537
-2,371
-2,874
-1,100
Pretax Income
43,780
28,604
38,968
35,965
10,422
Tax Provision
9,052
5,899
8,047
4,417
55
Net Income Common Stockholders
34,728
22,705
30,921
31,549
10,367
Diluted NI Available to Com Stockholders
34,728
22,705
30,921
31,549
10,367
Basic EPS
1.19
0.78
1.06
1.09
0.36
Diluted EPS
1.16
0.76
1.04
1.09
0.36
Basic Average Shares
29,063.61
29,063.61
29,063.61
29,063.61
29,063.61
Diluted Average Shares
29,138.61
29,063.61
29,525.61
29,555.61
29,063.61
Total Operating Income as Reported
52,771
32,615
41,339
38,839
11,445
Total Expenses
285,996
231,925
218,806
371,194
167,948
Net Income from Continuing & Discontinued Operation
34,728
22,705
30,921
31,549
10,367
Normalized Income
33,516.72
21,492.91
30,921
31,549
10,299.36
Interest Income
-1,523
195
1
0
0
Interest Expense
8,993
5,732
2,372
2,874
1,100
Net Interest Income
-10,516
-5,537
-2,371
-2,874
-1,100
EBIT
52,773
34,336
41,340
38,839
11,522
EBITDA
52,773
43,082
41,340
49,105
11,522
Reconciled Cost of Revenue
197,497
149,123
144,063
314,019
128,135
Reconciled Depreciation
--
8,746
14,185
10,266
17,275
Net Income from Continuing Operation Net Minority Interest
34,728
22,705
30,921
31,549
10,367
Total Unusual Items Excluding Goodwill
1,527
1,527
0
0
68
Total Unusual Items
1,527
1,527
0
0
68
Normalized EBITDA
51,246
41,555
41,340
49,105
11,454
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
315.72
314.91
0
0
0.36
3/31/2021 - 7/4/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CINPHA.ST Cinclus Pharma Holding AB (publ)
9.80
+2.08%
 
SECARE.ST Swedencare AB (publ)
41.00
+2.50%
 
MEDXF Medexus Pharmaceuticals Inc.
2.1010
+1.01%
 
ETST Earth Science Tech, Inc.
0.1500
0.00%
 
CTX.TO Crescita Therapeutics Inc.
0.5600
0.00%
 
INNO.CN InnoCan Pharma Corporation
0.1700
-2.86%
 
CPHRF Cipher Pharmaceuticals Inc.
9.97
-0.20%
 
CRNO-B.ST Cereno Scientific AB (publ)
8.92
+1.02%
 
VREOF Vireo Growth Inc.
0.3900
+5.41%
 
AVNT.TO Avant Brands Inc.
0.8500
0.00%